pharma · Retinitis Pigmentosa · Dyslipidaemia
HRA Pharma
Laboratoire HRA Pharma
HRA Pharma trial registry — 11 ClinicalTrials.gov studies with program phase, status, and indication context.
CHATILLON, USA HQ
121 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- CHATILLON, USA
- Employees
- 121
- Programs
- 11
- Drugs
- 17
- Patents
- 0
HRA Pharma clinical trials
Registry index of 11 ClinicalTrials.gov studies linked to HRA Pharma programs — each row shows trial ID, program name, phase, status, and indication.
HRA Pharma trial registry — 11 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for HRA Pharma.
-
SB-421a-006 — Phase 2
Clinical update -
SB-421a-006 — Phase 2
Clinical update -
ARG-01-2024 — Phase 3
Clinical update -
Coagulation Factor VIIa (Recombinant) — Phase 3
Clinical update -
D-CURE 25000 UI gélules., Placebo of vitamin D — Approved
Clinical update -
Pravafenix 40 mg/160 mg hard capsules — Phase 3
Clinical update -
Preservative-free, ophthalmic solution — Phase 2
Clinical update -
Placebo of NAL, NACYSTELYN — Phase 2
Clinical update